Resources

Cigna's GLP-1 Study and Report

This report reviews GLP-1 demand growth, budget pressure, and coverage strategy tradeoffs for plan sponsors and employers.

Home / Evidence & Performance / Cigna's GLP-1 Study and Report

FastHSR resource note with source citation.

Executive Summary

GLP-1 therapies are reshaping pharmacy trend, utilization patterns, and benefit strategy decisions for employers and health plans. This FastHSR summary highlights what decision-makers can take from the report: demand is rising quickly, the budget impact is material, and clinical value depends on patient selection, adherence support, and model design.

For leadership teams, the practical question is not whether GLP-1 demand exists, but how to manage access, affordability, and long-term outcomes at the same time.

How the report was built

The report combines a nationwide survey of consumers, employers, providers, pharmacists, and health plan leaders.
It includes claims analysis covering 28 million commercially insured individuals.
It also incorporates industry and scientific literature to contextualize utilization and cost trends.

Executive highlights

GLP-1 use is a major driver of traditional drug trend growth and budget pressure.
High discontinuation rates create uncertainty around realized long-term value.
Youth uptake is accelerating, which amplifies affordability and supply-planning concerns.

Why this matters for FastHSR clients

FastHSR applies these insights to market sizing, budget forecasting, formulary strategy, and scenario testing. We use iterative analytics with client feedback to translate broad trend signals into decision-grade actions.

Source citation

Evernorth Research Institute. Pharmacy in Focus: Navigating GLP-1 cost, demand and sustainability. Published March 25, 2025.

View original source

For more granular data, more recent data, or scientific analysis support, please email us.

Back to Evidence & Performance